NEW YORK – Credo Diagnostics Biomedical announced Friday its combination VitaPCR Influenza A&B/SARS-CoV-2 test received CE-IVD marking.
The point-of-care RT-PCR test delivers results from one nasopharyngeal sample in 20 minutes and can be used on the firm's VitaPCR instrument. The platform can perform 24 runs per day with one sample per run and doesn't need "highly trained personnel," Credo said in a presentation on the test.